Literature DB >> 25552608

Comparison of an automated rapid plasma reagin (RPR) test with the conventional RPR card test in syphilis testing.

Jong-Han Lee1, Chae Seung Lim1, Min-Geol Lee2, Hyon-Suk Kim3.   

Abstract

OBJECTIVE: We compared the automated non-treponemal reagin (rapid plasma reagin (RPR)) test with the conventional RPR card test for usefulness in clinical applications.
SETTING: A comparative study of laboratory methods using clinical specimens in a single institute. PARTICIPANTS: A total of 112 serum samples including 59 Treponema pallidum particle agglutination (TPPA)-positive and 53 TPPA-negative specimens were evaluated. OUTCOME MEASURES: HiSens Auto RPR LTIA (HBI, Anyang, Korea) was compared with Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, Maryland, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Tokyo, Japan). The percentage agreement, κ value and overall sensitivity and specificity of the two RPR tests were compared. Seroconversion rates after treatment were also compared for each RPR test.
RESULTS: The percentage agreement between the two RPR tests was 78.6% (κ 0.565; 95% CI 0.422 to 0.709). Sensitivity and specificity of the automated RPR test relative to the TPPA test was 52.5% (95% CI 39.1% to 65.7%) and 94.3% (95% CI 84.3% to 98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI 75% to 93.9%) and 94.3% (95% CI 84.3% to 98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed higher seroconversion (43.5%, 10/23) than the conventional RPR card test (4.3%, 1/23) in treated patients.
CONCLUSIONS: The automated RPR test showed overall lower sensitivity than the conventional RPR test based on the treponemal test, but higher seroconversion after treatment. The automated RPR test could be used to monitor treatment response, especially in the reverse screening algorithm in syphilis testing. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  IMMUNOLOGY

Mesh:

Substances:

Year:  2014        PMID: 25552608      PMCID: PMC4281540          DOI: 10.1136/bmjopen-2014-005664

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


Automated rapid plasma reagin (RPR) testing has been introduced in clinical laboratories, so we compared the automated test with the conventional RPR card tests. The automated RPR test showed overall lower positivity than the conventional RPR test compared with the treponemal test, Treponema pallidum particle agglutination (TPPA). The automated RPR test showed higher seroconversion after treatment than the conventional manual RPR test. So, the automated RPR test could be used to monitor treatment response, especially in the reverse screening algorithm for syphilis testing. Limitations of this study are small sample size and the patient groups could not be accurately categorised according to the stage of the disease because of the low prevalence of syphilis in Korea.

Introduction

There has been a rapid decrease in positive rates for syphilis since the 1970s in Korea, consistent with the global trend. In 2000, ∼0.2% of the general Korean population was estimated to be syphilis-positive; since that time, levels appear to have decreased, and the prevalence rate is still very low.1 Despite these low rates, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. Appropriate screening, confirmation and follow-up protocols are required.2–4 Serological analysis of non-treponemal reagin tests, such as the Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) and treponemal tests such as the Treponema pallidum haemagglutination assay (TPHA), the Treponema pallidum particle agglutination (TPPA) test, the fluorescent treponemal antibody absorption test, and the Treponema-specific antibody test, have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal- or treponemal-specific tests.2 5 6 The Centers for Disease Control and Prevention (CDC) still recommend that a non-treponemal reagin test is used as the first-line diagnostic approach.2 Two kinds of non-treponemal test have been widely used: VDRL and RPR. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.7 Recently, automated RPR tests have been introduced, but variable results were reported when the automated test was compared with conventional RPR card tests.8 The automated RPR test has some advantages over the conventional RPR card test, such as greater capacity to deal with a large number of samples, minimal person-to-person variation, and simple automated procedures. The aim of this study was to evaluate the possible benefits of an automated RPR test compared with a conventional RPR card test in clinical application.

Methods

Subjects

All sera testing positive for syphilis by one or more tests from November 2012 to April 2013 from a university hospital were included, along with matched controls. Remnant sera from requested treponemal tests after confirmation were included and preserved at −70°C until analysis. Patients were not categorised according to syphilis stage because of the infrequency of syphilis infection. Cases of true syphilis were very rare because of the low prevalence of syphilis in this country. The aim of this study was to evaluate the same RPR tests with ethically protected remnant specimens. This case was exempted by the institutional review board. All study processes complied with the World Medical Association Declaration of Helsinki. The automated RPR test was compared with the manual RPR card test (Becton Dickinson BD Microbiology Systems, Sparks, Maryland, USA). A confirmatory treponemal-specific test was performed using a TPPA assay according to the manufacturer's instructions. Seroconversion rates of each non-treponemal RPR test were evaluated on 23 syphilitic patients with a medical history of syphilis treatment.

Serological tests

Conventional RPR card test

The Macro-Vue RPR Card Test (Becton Dickinson BD Microbiology Systems) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test antigen, which consists of cardiolipinlecithincholesterol particles, causing macroscopic flocculation. Controls were established for each test to confirm optimal reactivity of the antigen. The test procedure was followed according to the manufacturer's instructions.

Automated RPR test

HiSens Auto RPR LTIA (HBI, Anyang, Korea) is a latex turbidimetric immunoassay using latex particles coated with lecithin and cardiolipin. The latex particles react with the reagin in the serum of patients with syphilis. The 15 μL serum samples were allowed to react with 120 μL Hisens auto RPR LTIA R1 (buffer) and 60 μL Hisens auto RPR LTIA R2 (latex reagent containing cardiolipinlecithincholesterol, 1.0 mg/mL) in a CA-400 autoanalyzer (Furuno Electric Co, Nishinomiya, Japan). The CA-400 photometric analyser was used for the automated procedure and analysis. Absorbance at 600 nm was read after 5.3 and 10 s at room temperature, in duplicate. Results of the HiSens auto RPR test equal to or greater than 1.0 RPR unit (RU) were considered to indicate reactive RPR. The upper detection limit was 20 RU.

Treponema pallidum particle agglutination

The Serodia TPPA assay (Fujirebio, Tokyo, Japan) is based on agglutination of coloured gelatine particles that have been sensitised (coated) with T. pallidum (Nichols strain) antigen. For each specimen, a 100 μL sample of diluent and 25 μL test specimen were mixed, and then twofold serial dilutions were made with 25 μL sample diluent. The sensitised particles were serially mixed in the neighbouring wells with a plate mixer for 30 s. After 2 h of incubation at room temperature, the result of the agglutination assay was read. The Serodia TPPA assay results were interpreted using the agglutination patterns of positive and negative controls.

Statistical analysis

The percentage agreement (κ coefficient) of the automated RPR test with the manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the TPPA results. κ values were used to categorise results as very good (0.81–1.0), good (0.61–0.8), moderate (0.41–0.6), fair (0.21–0.4) or poor (0–0.2).9 The McNemar test was used to compare seroconversion rates between the automated RPR test and the conventional manual RPR card test and was performed using SPSS Statistics V.20. A p value <0.05 was considered significant.

Results

A total of 112 serum samples from 59 patients with syphilis (48±21 years old; male/female ratio 25:34 (0.7)) and 53 non-syphilitic controls (45±17 years old; male/female ratio 27:26 (1)) after the treponemal test were collected from November 2012 to April 2013 in a university hospital in Korea. The percentage agreement between the two RPR tests was 78.6% (κ 0.565; 95% CI 0.422 to 0.709; table 1). The strength of agreement between the automated RPR test and the manual RPR card test was considered to be ‘moderate’ according to the κ value scale. Both RPR-positive results (n=32) showed 96.9% (31/32) TPPA-positive results, and both RPR-negative results (n=56) showed 85.7% (48/56) TPPA-negative results.
Table 1

Comparison of non-treponemal RPR tests for syphilis detection

HBI HiSens Auto RPR test
PositiveNegative
BD Macro-Vue RPR cardPositive3222*
Negative2†56
Number of observed agreements: 88 (78.6% of the observations)
κ=0.565
95% CI 0.422 to 0.709

*20 cases were positive and 2 cases (Nos 1 and 2 in table 2) were negative in the TPPA test.

†The 2 cases (Nos 3 and 4 in table 2) were negative in the TPPA test.

RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination.

Comparison of non-treponemal RPR tests for syphilis detection *20 cases were positive and 2 cases (Nos 1 and 2 in table 2) were negative in the TPPA test.
Table 2

RPR results that were discrepant with the treponemal test for diagnosis of syphilis

Case NoAge/sexRPR card testAutomated RPR (RPR unit)TPPAClinical diagnosis
128/F1+NegativeNegativeAtopic dermatitis, antiphospholipid syndrome
250/F1+NegativeNegativeBronchiectasis, secondary pulmonary hypertension
322/MNegative2.2NegativeBehcet's disease
433/MNegative1.1NegativeChlamydia, Herpes penis

RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination.

†The 2 cases (Nos 3 and 4 in table 2) were negative in the TPPA test. RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination. There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative HBI HiSens Auto RPR LTIA test results that showed positive results on the BD Macro-Vue RPR card test. Of these 22 discrepant results, 20 were TPPA-positive and 2 were TPPA-negative, while 2 cases were positive on the HBI HiSens Auto RPR LTIA test but negative on the BD Macro-Vue RPR card test. These two cases were negative on the TPPA test. There were four results with discrepancies between both the RPR tests and the TPPA assay, which was due to conditions other than syphilis infection (table 2). The strength of agreement between the automated RPR and manual RPR tests was ‘fair’ (κ value 0.296, 59 TPPA-positive results; κ value 0.293, 53 TPPA-negative results) according to the TPPA results (table 3).
Table 3

Comparison of non-treponemal RPR tests with TPPA test results

HBI HiSens Auto RPR
HBI HiSens Auto RPR
TPPA positive (n=59)PositiveNegativeTPPA negative (n=53)PositiveNegative
BD Macro-Vue RPR cardPositive3120BD Macro-Vue RPR cardPositive12
Negative08Negative248
Number of observed agreements: 39 (66.1% of the observations)Number of observed agreements: 49 (92.5% of the observations)
κ=0.296κ=0.293
95% CI 0.118 to 0.47495% CI −0.212 to 0.798

RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination.

RPR results that were discrepant with the treponemal test for diagnosis of syphilis RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination. Comparison of non-treponemal RPR tests with TPPA test results RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination. The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA results were 52.5% (95% CI 39.1% to 65.7%) and 94.3% (95% CI 84.3% to 98.8%), respectively. The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95% CI 75% to 93.9%) and 94.3% (95% CI 84.3% to 98.8%), respectively (table 4). Automated RPR gave a higher seroconversion rate after syphilis treatment (43.5% (10/23)) than the conventional RPR card test (4.3% (1/23)) (p=0.004) by the McNemar test. A detailed comparison of the treated syphilis cases is given in table 5.
Table 4

Performance characteristics of RPR tests for diagnosis of syphilis

Non-treponemal testsTPPA
PositiveNegative
HBI HiSens Auto RPRPositive313
Negative2850
Sensitivity52.5%(95% CI 39.1% to 65.7%)
Specificity94.3%(95% CI 84.3% to 98.8%)
Positive predictive value91.2%(95% CI 76.3% to 98%)
Negative predictive value64.1%(95% CI 52.4% to 74.7%)
TPPA
PositiveNegative
BD Macro-Vue RPR cardPositive513
Negative850
Sensitivity86.4%(95% CI 75% to 93.9%)
Specificity94.3%(95% CI 84.3% to 98.8%)
Positive predictive value94.4%(95% CI 84.6% to 98.8%)
Negative predictive value86.2%(95% CI 74.6% to 93.8%)

RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination.

Table 5

Comparison of manual and automated RPR test after initial syphilis treatment

CaseNoAgeGenderManualRPRAutomatedRPR (RU)TPPAPretreatmentVDRL test valueTime after initial treatment (days)Initial treatmentDiagnosis
154Male2+01:51201:8 reactive939Penicillin G benzathine 1.2×106 IUSyphilis, latent
266Male0.5+01:6401:1 weakly reactive903Penicillin G benzathine 1.2×106 IUTreated syphilis
317Male2+01:51201:4 reactive222Penicillin G benzathine 1.2×106 IUSyphilis, late, latent
462Male2+01:6401:1 reactive296Penicillin G benzathine 1.2×106 IUSyphilis, other and unspecified
568Male1+01:3201:1 weakly reactive644Penicillin G benzathine 1.2×106 IUSyphilis, late, latent
672Male1+01:6401:1 weakly reactive28Penicillin G benzathine 1.2×106 IUSyphilis, late, unspecified
755Female001:1280N/A0Penicillin G benzathine 1.2×106 IUSyphilis, latent
856Female1+01:51201:1 weakly reactive7Penicillin G benzathine 1.2×106 IUSyphilis, latent
965Female2+01:801:1 reactive0Penicillin G benzathine 1.2×106 IUSyphilis, late
1033Female1+01:51201:8 reactive936Penicillin G benzathine 1.2×106 IUSyphilis, other and unspecified
1128Female2+11:25601:1 reactive1097Penicillin G benzathine 1.2×106 IUSyphilis, late, latent
122Male2+1.11:51201:32 reactive539Penicillin G benzathine 1.2×106 IUSyphilis, congenital, latent
1365Male3+1.31:6401:1 reactive273Penicillin G Benzathine 1.2×106 IUTreated syphilis
1470Male3+2.31:12801:1 reactive188Doxycycline 100 mgSyphilis, late, latent
1548Female2+2.51:51201:1 weakly reactive665Penicillin G benzathine 1.2×106 IUTreated syphilis
1636Female2+3.81:51201:2 reactive810Penicillin G benzathine 1.2×106 IUSyphilis, latent
1774Female4+7.71:3201:4 reactive669Penicillin G benzathine 1.2×106 IUSyphilis, late, latent
1825Female4+8.11:51201:8 reactive172Penicillin G benzathine 1.2×106 IUSyphilis with pregnancy
1964Female4+14.11:51201:8 reactive0Penicillin G benzathine 1.2×106 IUChronic rhinitis
2030Male4+201:25601:16 reactive7Penicillin G benzathine 1.2×106 IUSyphilis, late, unspecified
2131Female2+201:51201:16 reactive3Penicillin G benzathine 1.2×106 IUSyphilis with pregnancy
2251Female4+20.41:51201:8 reactive417Penicillin G benzathine 1.2×106 IUSyphilis, latent
2337Female2+25.61:51201:16 reactive0Penicillin G benzathine 1.2×106 IUTreated syphilis

N/A, not applicable; RPR, rapid plasma reagin; RU, RPR unit; TPPA, Treponema pallidum particle agglutination; VDRL, Venereal Disease Research Laboratory.

Performance characteristics of RPR tests for diagnosis of syphilis RPR, rapid plasma reagin; TPPA, Treponema pallidum particle agglutination. Comparison of manual and automated RPR test after initial syphilis treatment N/A, not applicable; RPR, rapid plasma reagin; RU, RPR unit; TPPA, Treponema pallidum particle agglutination; VDRL, Venereal Disease Research Laboratory.

Discussion

The manual RPR test has been used for decades, but recently an automated RPR test was launched and has been used because of its convenience in clinical settings. However, there was a need for thorough inspection and a comparison of results of this new automated test with the conventional manual RPR test in diagnostic approaches. Treponemal test results will not change even after treatment, and the patients live with positive results for the rest of their lives regardless of treatment or disease activity. Treponemal tests cannot discriminate between past infections, active disease, treated patients and non-treated patients.10 In contrast, non-treponemal tests can discriminate between patients who have been treated during the primary or secondary stage of the disease. When the primary or secondary stage of a first T. pallidum infection is treated, the non-treponemal test titre should show a twofold dilution decline after treatment, usually within 6 months.7 Therefore, the non-treponemal test is important for managing syphilitic patients. We compared an automated RPR test with a conventional RPR card test on sera confirmed by the TPPA test. The TPPA test is known to be less subjective than the fluorescent treponemal antibody absorption test and easier to read than the microhaemagglutination assay for antibodies to T. pallidum.11 The TPPA test has also been suggested for use on cerebrospinal fluid samples for diagnosing neurosyphilis.12 In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than the HBI HiSens Auto RPR LTIA test in syphilis screening, although the automated RPR test does have some advantages in the clinical setting. For example, the automated RPR test reduced the workload and overall test turnaround time. It can also deal with greater test quantities in a given time than the manual RPR card test and does not require test experts. Furthermore, we observed that the automated RPR test could be used as a monitoring marker of treatment response, especially if treponemal tests are used for first-line screening of syphilis as a reverse algorithm of syphilis testing. This reverse algorithm for syphilis testing has been suggested and adopted in many fields because it may be more sensitive and effective than the traditional algorithm3 4 6 in a low-prevalence area and can be automated. However, the CDC still recommend first screening for syphilis with a non-treponemal test such as RPR.2 Our study found that the automated RPR test showed earlier seroconversion than the conventional card RPR test after syphilis treatment (p=0.004). If we adopt the reverse algorithm, treponemal tests can be used first to screen sensitively, and then non-treponemal tests can be used to accurately show negative changes in treated cases. In this situation, we could use treponemal tests for first-line screening and non-treponemal tests for monitoring patients allowing us to observe seroconversion more effectively after treatment.2 13 14 Unfortunately, our study had a limited number of syphilitic patients because of the low prevalence of syphilis in our country, so the number of samples was small and could not been classified according to syphilis stage. In fact, in some late or latent syphilis cases, the results of the non-treponemal test were hard to interpret after initial treatment in our study (cases 8 and 9 in table 5). So, further well-designed studies are needed to clarify the serological responses of automated RPR tests after treatment and according to the stage of syphilis infection. In Korea, automated RPR tests have recently been introduced in clinical laboratories, and evaluations comparing conventional RPR tests and VDRL tests have been reported.8 15 However, the results were variable. Onoe et al16 also suggested that, when the automated serological testing method is used in clinical settings, the same reagent should be consistently selected to evaluate the changes in antibody titres, because the manual serological testing method for syphilis showed somewhat different results from the automated serological testing methods. In this study, we noticed reasonably consistent results between automated and manual RPR tests. We found that the automated RPR test has greater processing capability within a limited time and is effectively applicable. Through the reverse syphilis screening algorithm, we can increase the detection sensitivity of syphilis screening by using the treponemal test for initial screening, and then the automated RPR test after treatment because of its rapid seroconversion, although the sensitivity of the automated RPR test is lower than that of the manual RPR test. In conclusion, the automated RPR test showed an overall lower sensitivity and similar specificity compared with the conventional manual RPR card test. Therefore, we consider that the automated RPR test is not appropriate for use for initial screening for syphilis. However, it produces an earlier seroconversion response in treated cases than the conventional RPR card test. Applying the reverse algorithm, the sensitive treponemal test can be used as the first-line screening test, and then the automated RPR test can be used as an adjunct to detect earlier seroconversion in treated patients. Further large-scale studies including patients categorised by syphilis stage are required to clarify the diagnostic efficiency of the automated RPR test.
  15 in total

1.  Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group.

Authors:  S I Egglestone; A J Turner
Journal:  Commun Dis Public Health       Date:  2000-09

2.  Evaluation of the Treponema pallidum particle agglutination technique (TP.PA) in the diagnosis of neurosyphilis.

Authors:  Rita Castro; Emília S Prieto; Maria João Aguas; Maria José Manata; Júlio Botas; Carlos Araújo; Fernando Borges; Isabel Aldir; Filomena da L Exposto
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  IUSTI: 2008 European Guidelines on the Management of Syphilis.

Authors:  P French; M Gomberg; M Janier; B Schmidt; P van Voorst Vader; H Young
Journal:  Int J STD AIDS       Date:  2009-05       Impact factor: 1.359

4.  [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test].

Authors:  Yeong Sic Kim; Jehoon Lee; Hae Kyung Lee; Hyunjung Kim; Hi Jeong Kwon; Ki Ouk Min; Eun Joo Seo; Soo-Young Kim
Journal:  Korean J Lab Med       Date:  2009-08

Review 5.  Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century.

Authors:  Arlene C Seña; Becky L White; P Frederick Sparling
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

8.  Serologic response to treatment of infectious syphilis.

Authors:  B Romanowski; R Sutherland; G H Fick; D Mooney; E J Love
Journal:  Ann Intern Med       Date:  1991-06-15       Impact factor: 25.391

9.  Evaluation of the passive particle agglutination test in the serodiagnosis and follow-up of syphilis.

Authors:  R R Castro; E S Prieto; I Santo; J Azevedo; F L Exposto
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

10.  Syphilis prevalence has rapidly decreased in South Korea.

Authors:  Y-H Cho; H O Kim; J-B Lee; M-G Lee
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

View more
  8 in total

1.  Usefulness of Automated Latex Turbidimetric Rapid Plasma Reagin Test for Diagnosis and Evaluation of Treatment Response in Syphilis in Comparison with Manual Card Test: a Prospective Cohort Study.

Authors:  Motoyuki Tsuboi; Takeshi Nishijima; Takahiro Aoki; Katsuji Teruya; Yoshimi Kikuchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

2.  Comparison of Manual and Fully Automated AIX1000 Rapid Plasma Reagin Assays for Laboratory Diagnosis of Syphilis.

Authors:  Alan M Sanfilippo; Kristie Freeman; John L Schmitz
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

3.  Comparison of RPR and ELISA with TPHA for the Diagnosis of Syphilis: Implication for Updating Syphilis Point-of-Care Tests in Ethiopia.

Authors:  Markos Negash; Tadelo Wondmagegn; Demeke Geremew
Journal:  J Immunol Res       Date:  2018-07-08       Impact factor: 4.818

4.  Effectiveness and Tolerability of Oral Amoxicillin in Pregnant Women with Active Syphilis, Japan, 2010-2018.

Authors:  Takeshi Nishijima; Kei Kawana; Ichio Fukasawa; Naoko Ishikawa; Melanie M Taylor; Hiroshige Mikamo; Kiyoko Kato; Jo Kitawaki; Tomoyuki Fujii
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

5.  Syphilis Laboratory Guidelines: Performance Characteristics of Nontreponemal Antibody Tests.

Authors:  Susan Tuddenham; Samantha S Katz; Khalil G Ghanem
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

6.  Serological tests for syphilis.

Authors:  Dhiral Shah; Yogesh S Marfatia
Journal:  Indian J Sex Transm Dis AIDS       Date:  2019 Jul-Dec

7.  Serologic Response to Treatment in Human Immunodeficiency Virus-Negative Syphilis Patients Using Automated Serological Tests: Proposals for New Guidelines.

Authors:  Jung-In Kim; Ji-Hye Park; Ju-Yeon Choi; Ga-Young Lee; Won-Serk Kim
Journal:  Ann Dermatol       Date:  2017-10-30       Impact factor: 1.444

8.  Traditional versus reverse syphilis algorithms: A comparison at a large academic medical center.

Authors:  Craig D Dunseth; Bradley A Ford; Matthew D Krasowski
Journal:  Pract Lab Med       Date:  2017-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.